Sections View Full Chapter Figures Tables Videos Annotate Full Chapter Figures Tables Videos Supplementary Content +++ Abbreviations ++Table Graphic Jump Location|Download (.pdf)|PrintABLCAmphotericin B lipid complexABMAcute bacterial meningitisAUCArea under the curveCAPCommunity-acquired pneumoniaCDIClostridium difficile infectionCLSIClinical Laboratory Standards InstituteCNSCentral nervous systemCRBSICatheter-related bloodstream infectionsCSFCerebrospinal fluidEUCASTEuropean Committee on Antimicrobial Susceptibility TestingHAPHospital-acquired pneumoniaIAIIntra-abdomnial infectionsIBWIdeal body weightIEInfective endocarditisLAMBLiposomal amphotericin BMICMinimum inhibitory concentrationMRSAMethicillin-resistant Staphylococcus aureusMSSAMethicillin-susceptible Staphylococcus aureusPCNPenicillinPDPharmacodynamicPKPharmacokineticSSTISkin and soft tissue infectionsTBWTotal body weightUTIsUrinary tract infectionsVREVancomycin-resistant enterococcusWBCWhite blood cell++Table Graphic Jump LocationTable 2.1.1 General Approach to Infectious DiseasesView Table||Download (.pdf)Table 2.1.1 General Approach to Infectious DiseasesStep One: Confirm InfectionGeneral signs and symptoms of infection include:Temperature >101°F (>100.4°F in some instances)WBC >10 with bands >10%Assess for infection-specific signs/symptoms according to algorithmsStep Two: Perform Diagnostic Tests/WorkupEnsure that cultures are obtained from the site of the infection BEFORE antimicrobial administrationGram stain and morphology from culture results may further guide empiric selectionAssess for severity of infection according to algorithmsStep Three: Start Empiric TherapyReview list of likely infectious etiologies according to the algorithms that are largely based on infection siteStart empiric therapy according to algorithms (base decision on local susceptibility patterns where possible, that is, antibiograms)Empiric antimicrobial dosing recommendations can be found in Tables 2.1.2, 2.1.3 and 2.1.4Step Four: Reevaluate/Monitor Response to TherapyCheck for resolution of signs and symptomsFollow-up culture results/susceptibilities and note MIC when availableUse Table 2.1.5 to monitor for adverse effects associated with selected empiric therapy and serum concentrations where necessaryStep Five: Streamline/Narrow Antimicrobial TherapyUse the most narrow spectrum antimicrobial that is susceptible from culture resultsIf MIC results are available, consider selecting an antimicrobial with an MIC well below susceptibility breakpoints found in Table 2.1.6 (NOTE: MICs should NOT be compared across different antimicrobials)ExampleBlood Culture Results: Escherichia coliS/I/RMICBreakpointAmpicillin/sulbactamR>32≤8←ResistantCefepimeS2≤8←Compare MIC = 2 to breakpoint ≤8 (“very susceptible”)CeftriaxoneI2≤1←IntermediateCiprofloxacinS1≤1←Compare MIC = 1 to breakpoint ≤1 (“susceptible”)In the example above, cefepime may be selected over ciprofloxacin because the cefepime MIC is well below the cefepime E. coli susceptibility breakpoint of ≤8. The ciprofloxacin MIC is equivalent to the ciprofloxacin E. coli susceptibility breakpoint of ≤1. If ciprofloxacin is more appropriate for the patient, then PK–PD dosing should be optimized (Table 2.1.3).++Table Graphic Jump LocationTable 2.1.2 Dosing Regimens for Commonly Selected Intravenous AntimicrobialsView Table||Download (.pdf)Table 2.1.2 Dosing Regimens for Commonly Selected Intravenous AntimicrobialsRecommended Dosing for Susceptible OrganismsClass/DrugsInfection/PathogenNormal Dose (Infusion Time)CrCl 30–59CrCl 15–29CrCl ... Your Access profile is currently affiliated with [InstitutionA] and is in the process of switching affiliations to [InstitutionB]. Please select how you would like to proceed. Keep the current affiliation with [InstitutionA] and continue with the Access profile sign in process Switch affiliation to [InstitutionB] and continue with the Access profile sign in process Get Free Access Through Your Institution Learn how to see if your library subscribes to McGraw Hill Medical products. Subscribe: Institutional or Individual Sign In Error: Incorrect UserName or Password Username Error: Please enter User Name Password Error: Please enter Password Sign in Forgot Password? Forgot Username? Download the Access App: iOS | Android Sign in via OpenAthens Sign in via Shibboleth You already have access! Please proceed to your institution's subscription. Create a free profile for additional features.